- Avicanna (AVCN) appoints Stephen Kim to Chief Legal Officer & General Counsel
- Kim comes with over twenty years of legal experience with highly regulated and innovative industries
- Kim will join Avicanna at his role as the Chief Legal Officer on January 17, 2022
- Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development, and evidence-based products
- It actively collaborates with leading Canadian academic and medical institutions
- Avicanna Inc. (AVCN) is down 8.96 per cent, trading at C$0.61 at 3:59 pm EST
Avicanna USA Inc. together with Avicanna Inc. (AVCN) has appointed Stephen Kim as Avicanna’s Chief Legal Officer & General Counsel.
Mr. Kim has over twenty years of legal experience with highly regulated and innovative industries.
He has prior pharmaceutical industry experience and is familiar with the complex overlay of corporate, commercial, IP, governance, compliance, and regulatory considerations associated with the development, approval, and launch of multiple pharmaceutical products, which he has executed in the US, Canada, and globally.
Prior to joining Avicanna, Kim held various roles at global biotechnology and pharmaceutical companies including Bayer Inc., Celgene Corporation, and Indivior Inc. He also held associate roles with leading U.S. and International law firms in New York City and Toronto.
Kim graduated with law degrees from the University of Detroit Mercy (JD) and the University of Windsor (LLB).
Stephen Kim commented,
“With my background and experience in domestic and cross-border transactions, as well as pharmaceutical product development, approval, and launch, I am particularly excited about the company’s work in the areas of evidence-based and pharmaceutical products and global business.”
“Stephen’s experience and track record coupled with his alignment of vision with the Management Team is precisely what the company needs to achieve its growth potential,” said Aras Azadian, Chief Executive Officer.
Kim will join Avicanna in his role as the Chief Legal Officer on January 17, 2022, where he will oversee all legal and regulatory affairs at a global level.
Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development, and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments.
In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District.
It actively collaborates with leading Canadian academic and medical institutions.
Avicanna Inc. (AVCN) is down 8.96 per cent, trading at C$0.61 at 3:59 pm EST.
